8 References [1] G. Y. Oudit and J. M. Penninger, “Recombinant human angiotensin-converting enzyme 2 as a new renin-angiotensin system peptidase for heart failure therapy,” Current Heart Failure Reports, vol. 8, no. 3, pp. 176–183, 2011. [2] W. Wang, S. Bodiga, S. K. Das, J. Lo, V. Patel, and G. Y. Oudit, “Role of ACE2 in diastolicand systolic heart failure,” Heart Failure Reviews. In press. [3] A. Z. Kalea and D. Batlle, “Apelin and ACE2 in cardiovascular disease,” Current Opinion in Investigational Drugs, vol. 11, no. 3, pp. 273–282, 2010. [4] C. Vickers, P. Hales, V. Kaushik et al., “Hydrolysis of bio- logical peptides by human angiotensin-converting enzyme- related carboxypeptidase,” Journal of Biological Chemistry, vol. 277, no. 17, pp. 14838–14843, 2002. [5] B. Chandrasekaran, O. Dar, and T. McDonagh, “The role of apelin in cardiovascular function and heart failure,” European Journal of Heart Failure, vol. 10, no. 8, pp. 725–732, 2008. [6] J. Zhong, R. Basu, D. Guo et al., “Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial ﬁbrosis, and cardiac dysfunction,” Circulation, vol. 122, no. 7, pp. 717–728, 2010. [7] G. Y. Oudit, Y. Imai, K. Kuba, J. W. Scholey, and J. M. Pen- ninger, “The role of ACE2 in pulmonary diseases - relevance for the nephrologist,” Nephrology Dialysis Transplantation, vol. 24, no. 5, pp. 1362–1365, 2009. [8] G. Wang, F. M. Lai, B. C. Kwan et al., “Expression of ACE and ACE2 in patients with hypertensive nephrosclerosis,” Kidney and Blood Pressure Research, vol. 34, no. 3, pp. 141–149, 2011. [9] J. C. Zhong, J. Y. Ye, H. Y. Jin et al., “Telmisartan attenuates aortic hypertrophy in hypertensive rats by the modulation of ACE2 and proﬁlin-1 expression,” Regulatory Peptides, vol. 166, no. 1–3, pp. 90–97, 2011. [10] C. Diez-Freire, J. Vazquez, M. F. Correa de Adjounian et al., “ACE2 gene transfer attenuates hypertension-linked patho- physiological changes in the SHR,” Physiological Genomics, vol. 27, pp. 12–19, 2006. [11] B. Rentzsch, M. Todiras, R. Iliescu et al., “Transgenic angiot- ensin-converting enzyme 2 overexpression in vessels of shrsp rats reduces blood pressure and improves endothelial func- tion,” Hypertension, vol. 52, no. 5, pp. 967–973, 2008. [12] S. Sriramula, J. P. Cardinale, E. Lazartigues, and J. Francis, “ACE2 overexpression in the paraventricular nucleus atten- uates angiotensin II-induced hypertension,” Cardiovascular Research, vol. 92, pp. 401–408, 2011. [13] J. Wysocki, M. Ye, E. Rodriguez et al., “Targeting the degra- dation of angiotensin ii with recombinant angiotensin- converting enzyme 2: prevention of angiotensin ii-dependent hypertension,” Hypertension, vol. 55, no. 1, pp. 90–98, 2010. [14] M. Przewlocka-Kosmala, T. Kotwica, A. Mysiak, and W. Kosmala, “Reduced circulating apelin in essential hyperten- sion and its association with cardiac dysfunction,” Journal of Hypertension, vol. 29, no. 5, pp. 971–979, 2011. [15] A. Sonmez, G. Celebi, G. Erdem et al., “Plasma apelin and adma levels in patients with essential hypertension,” Clinical and Experimental Hypertension, vol. 32, no. 3, pp. 179–183, 2010. [16] W. W. Li, W. Q. Niu, Y. Zhang, S. Wu, P. J. Gao, and D. L. Zhu, “Family-based analysis of apelin and agtrl1 gene pol- ymorphisms with hypertension in han chinese,” Journal of Hypertension, vol. 27, no. 6, pp. 1194–1201, 2009. Cardiology Research and Practice [17] K. Tatemoto, K. Takayama, M. X. Zou et al., “The novel peptide apelin lowers blood pressure via a nitric oxide- dependent mechanism,” Regulatory Peptides, vol. 99, no. 2-3, pp. 87–92, 2001. [18] X. Cheng, X. S. Cheng, and C. C. Pang, “Venous dilator eﬀect of apelin, an endogenous peptide ligand for the orphan APJ receptor, in conscious rats,” European Journal of Pharmacol- ogy, vol. 470, no. 3, pp. 171–175, 2003. [19] A. G. Japp, N. L. Cruden, D. A. Amer et al., “Vascular eﬀects of apelin in vivo in man,” Journal of the American College of Cardiology, vol. 52, no. 11, pp. 908–913, 2008. [20] V. Shenoy, Y. Qi, M. J. Katovich, and M. K. Raizada, “ACE2, a promising therapeutic target for pulmonary hypertension,” Current Opinion in Pharmacology, vol. 11, no. 2, pp. 150–155, 2011. [21] Y. Yamazato, A. J. Ferreira, K. H. Hong et al., “Prevention of pulmonary hypertension by angiotensin-converting enzyme 2 gene transfer,” Hypertension, vol. 54, no. 2, pp. 365–371, 2009. [22] A. J. Ferreira, V. Shenoy, Y. Yamazato et al., “Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension,” American Jour- nal of Respiratory and Critical Care Medicine, vol. 179, no. 11, pp. 1048–1054, 2009. [23] J. A. Johnson, J. West, K. B. Maynard, and A. R. Hemnes, “ACE2 improves right ventricular function in a pressure over- load model,” Plos one, vol. 6, no. 6, Article ID e20828, 2011. [24] M. J. Kleinz and A. P. Davenport, “Immunocytochemical localization of the endogenous vasoactive peptide apelin to human vascular and endocardial endothelial cells,” Regula- tory Peptides, vol. 118, no. 3, pp. 119–125, 2004. [25] S. M. Chandra, H. Razavi, J. Kim et al., “Disruption of the apelin-APJ system worsens hypoxia-induced pulmonary hy- pertension,” Arteriosclerosis, Thrombosis, and Vascular Biol- ogy, vol. 31, no. 4, pp. 814–820, 2011. [26] T. P. Alastalo, M. Li, J. Perez Vde et al., “Disruption of PPARgamma/beta-catenin-mediated regulation of apelin impairs BMP-induced mouse and human pulmonary arterial EC survival,” The Journal of Clinical Investigation, vol. 121, no. 9, pp. 3735–3746, 2011. [27] I. Falca˜o-Pires, N. Gonc¸alves, T. Henriques-Coelho, D. Moreira-Gonc¸alves, R. Roncon-Albuquerque, and A. F. Leite- Moreira, “Apelin decreases myocardial injury and improves right ventricular function in monocrotaline-induced pul- monary hypertension,” American Journal of Physiology, vol. 296, no. 6, pp. H2007–H2014, 2009. [28] C. X. Liu, Q. Hu, Y. Wang et al., “Angiotensin-converting enzyme (ace) 2 overexpression ameliorates glomerular injury in a rat model of diabetic nephropathy: a comparison with ace inhibition,” Molecular Medicine, vol. 17, no. 1-2, pp. 59– 69, 2011. [29] A. Shiota, K. Yamamoto, M. Ohishi et al., “Loss of ACE2 accelerates time-dependent glomerular and tubulointerstitial damage in streptozotocin-induced diabetic mice,” Hyperten- sion Research, vol. 33, no. 4, pp. 298–307, 2010. [30] G. Y. Oudit, A. M. Herzenberg, Z. Kassiri et al., “Loss of angiotensin-converting enzyme-2 leads to the late devel- opment of angiotensin ii-dependent glomerulosclerosis,” American Journal of Pathology, vol. 168, no. 6, pp. 1808–1820, 2006. [31] H. N. Reich, G. Y. Oudit, J. M. Penninger, J. W. Scholey, and A. M. Herzenberg, “Decreased glomerular and tubular ex- pression of ACE2 in patients with type 2 diabetes and kidney